Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

NCT06463028 is registered in ClinicalTrials.gov with Faeth Therapeutics as lead sponsor.

NCT NCT06463028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06463028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer
Lead sponsor
Faeth Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2024
Completion date
September 30, 2029
Enrollment
40 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer